Biotech Values

[DewDiligence]

JAK inhibitors—including ABBV’s Rinvoq and PFE’s Xeljanz—have new FDA labels that relegate these agents to the second-line setting in RA (and other inflammatory diseases) following unsuccessful treatment with a TNFa agent (such as Humira); today’s label changes are in addition to the safety warnings added to the JAK labels three months ago (#msg-165728499).

ABBV’s PR:
https://finance.yahoo.com/news/abbvie-provides-rinvoq-upadacitinib-treatment-211500945.html

Please see #msg-165728499 for related info.

Note: BMY’s TYK2 inhibitor, Deucravacitinib is not affected by the above changes because the FDA considers TYK2 a different drug class from JAK.